LimmaTech Biologics
PrivateLast Round
Grant
Feb 17, 2025
Total Funding Raised
$51.87M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
LimmaTech Biologics is a biopharmaceutical company that specializes in the research, development, and production of innovative bioconjugate vaccines to prevent life-threatening diseases caused by antimicrobial-resistant pathogens.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
LimmaTech Biologics Comparables
Compare LimmaTech Biologics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Omniose | 87% | |
| EveliQure Biotechnologies | 77% | |
| Inventprise | 76% |
LimmaTech Biologics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Feb 17, 2025 | ||||
| Grant | Feb 27, 2024 | ||||
| Series A Extension | Feb 1, 2024 | ||||
| Series A | Oct 9, 2023 | ||||
| Seed | Oct 1, 2017 |
Key People
Founding team and executive leadership
LimmaTech Biologics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| CARB-X | Grant |
| AXA IM Alts | Series A Extension, Series A |
| Novo Holdings | Series A |
| BNP Paribas Asset Management | Series A |
| AXA Investment Managers | Series A |
| Adjuvant Capital | Series A Extension, Series A |
| Tenmile | Series A, Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors grew 524% MoM, reaching 6.5K.
- Jun 23, 2026
Monthly visitors grew 74% MoM, reaching 1K.
LimmaTech Biologics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about LimmaTech Biologics's valuation, stock price, and market status.
Is LimmaTech Biologics a public or private company?
LimmaTech Biologics is a private company.
What is the current stock price of LimmaTech Biologics?
LimmaTech Biologics is a private company with no public stock price. No recent secondary market data is available.
How much is LimmaTech Biologics worth (valuation)?
Valuation information for LimmaTech Biologics is not publicly available.
Can I buy LimmaTech Biologics stock?
LimmaTech Biologics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was LimmaTech Biologics's last funding round?
LimmaTech Biologics's most recent funding round was Grant on February 17, 2025.
Who are the main investors in LimmaTech Biologics?
Key investors in LimmaTech Biologics include AXA IM Alts, Novo Holdings, AXA Investment Managers, Adjuvant Capital, Tenmile.
Will LimmaTech Biologics IPO soon?
No public IPO plans have been announced for LimmaTech Biologics.
How can I track LimmaTech Biologics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor LimmaTech Biologics's secondary market activity and sign up for updates.